Prof. Carolyn Lam recognizes six mechanisms that play a role in the pathophysiology of HFpEF. She shares evidence why these mechanisms may be targeted for therapy.

Prof. De Boer summarises the interplay between obesity, diabetes and HFpEF, and how the first two conditions may be managed, to minimize their impact on the course of HFpEF.

Dr. Kotecha explains how the pathophysiologies of HFpEF and atrial fibrillation are interconnected, and what this means for management of patients with both conditions.

Slides as educational service to PACE members and meeting participants

Slides as educational service to PACE members and meeting participants